Influence of chitosan thioglycolic acid conjugate in improving bioavailability of an antiparkinson drug; Rasagiline Mesylate from transdermal patch
OBJECTIVE: Parkinson disease (PD) is a chronic disorder of central nervous system mainly affecting the motor systems. The drug of choice to treat PD is Rasagiline Mesylate (RM) and it belongs to BCS class III drug. The objective of the present study was the preparation of transdermal drug delivery system for RM. Several permeation enhancers were screened to be included in the formulation. To achieve desired flux a new strategy was developed by including in-house prepared CTC to enhance the permeation of RM.
METHODS: The CTC was prepared by reaction between chitosan and thioglycolicacid, characterized by determining physical properties and applying analytical tools. Seven permeation enhancers with different mechanisms were screened. The transdermal patches were prepared with chitosan along with permeation enhancer IPM, various proportions of CTC and evaluated for physical and permeation studies. The optimized transdermal patch was obtained by two factors and three responses to obtain the design space and further evaluated for pharmacokinetic studies.
RESULTS: The results of the present study confirmed the formation of CTC, IPM was best permeation enhancer among all. The presence of CTC in the formulations significantly improved the permeation of RM to achieve desired steady-state flux. The relative bioavailability of optimized transdermal patch was determined and it was observed that improved bioavailability as compared to marketed conventional tablets.
CONCLUSION: The study was concluded that CTC has significant influence on permeation enhancing ability of IPM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Drug development and industrial pharmacy - 47(2021), 6 vom: 17. Juni, Seite 963-976 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rohith, G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
003N66TS6T |
|---|
| Anmerkungen: |
Date Completed 13.08.2021 Date Revised 25.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/03639045.2021.1957919 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328288101 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328288101 | ||
| 003 | DE-627 | ||
| 005 | 20231225202631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03639045.2021.1957919 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1094.xml |
| 035 | |a (DE-627)NLM328288101 | ||
| 035 | |a (NLM)34283682 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rohith, G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Influence of chitosan thioglycolic acid conjugate in improving bioavailability of an antiparkinson drug; Rasagiline Mesylate from transdermal patch |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.08.2021 | ||
| 500 | |a Date Revised 25.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: Parkinson disease (PD) is a chronic disorder of central nervous system mainly affecting the motor systems. The drug of choice to treat PD is Rasagiline Mesylate (RM) and it belongs to BCS class III drug. The objective of the present study was the preparation of transdermal drug delivery system for RM. Several permeation enhancers were screened to be included in the formulation. To achieve desired flux a new strategy was developed by including in-house prepared CTC to enhance the permeation of RM | ||
| 520 | |a METHODS: The CTC was prepared by reaction between chitosan and thioglycolicacid, characterized by determining physical properties and applying analytical tools. Seven permeation enhancers with different mechanisms were screened. The transdermal patches were prepared with chitosan along with permeation enhancer IPM, various proportions of CTC and evaluated for physical and permeation studies. The optimized transdermal patch was obtained by two factors and three responses to obtain the design space and further evaluated for pharmacokinetic studies | ||
| 520 | |a RESULTS: The results of the present study confirmed the formation of CTC, IPM was best permeation enhancer among all. The presence of CTC in the formulations significantly improved the permeation of RM to achieve desired steady-state flux. The relative bioavailability of optimized transdermal patch was determined and it was observed that improved bioavailability as compared to marketed conventional tablets | ||
| 520 | |a CONCLUSION: The study was concluded that CTC has significant influence on permeation enhancing ability of IPM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antiparkinson | |
| 650 | 4 | |a LCMS/MS | |
| 650 | 4 | |a chitosan conjugate | |
| 650 | 4 | |a optimization | |
| 650 | 4 | |a rasagiline | |
| 650 | 4 | |a transdermal patch | |
| 650 | 7 | |a Indans |2 NLM | |
| 650 | 7 | |a Mesylates |2 NLM | |
| 650 | 7 | |a Tablets |2 NLM | |
| 650 | 7 | |a Thioglycolates |2 NLM | |
| 650 | 7 | |a rasagiline |2 NLM | |
| 650 | 7 | |a 003N66TS6T |2 NLM | |
| 650 | 7 | |a 2-mercaptoacetate |2 NLM | |
| 650 | 7 | |a 7857H94KHM |2 NLM | |
| 650 | 7 | |a Chitosan |2 NLM | |
| 650 | 7 | |a 9012-76-4 |2 NLM | |
| 700 | 1 | |a Satheesha Babu, B K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug development and industrial pharmacy |d 1994 |g 47(2021), 6 vom: 17. Juni, Seite 963-976 |w (DE-627)NLM077783093 |x 1520-5762 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2021 |g number:6 |g day:17 |g month:06 |g pages:963-976 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/03639045.2021.1957919 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2021 |e 6 |b 17 |c 06 |h 963-976 | ||